TrialAllergy2022
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.
Jonathan Corren et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
68 papers cite itlatest 60 shown
this paperpooled ittrialcites it
TrialAllergy2022
Jonathan Corren et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.